Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on th...
Iovance Biotherapeutics (formerly traded as Lio...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headq...
Spok, Inc., a wholly owned subsidiary of Spok H...
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibi...
Summit Therapeutics is a leader in antibiotic i...
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic a...
Lipocine Inc. is a clinical-stage biopharmaceut...
Conatus Pharmaceuticals is a biotechnology company focused on the development and ...
Conatus Pharmaceuticals is a biotechnology comp...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Join the National Investor Network and get the latest information with your interests in mind.